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Abstract
Purpose of Review Repurposing established medicines for a new therapeutic indication potentially has important global and societal
impact. The high costs and slow pace of new drug development have increased interest in more cost-effective repurposed drugs,
particularly in the cancer arena. The conventional drug development pathway and evidence framework are not designed for drug
repurposing and there is currently no consensus on establishing the evidence base before embarking on a large, resource intensive,
potential practice changing phase III randomised controlled trial (RCT). Numerous observational studies have suggested a potential role
for statins as a repurposed drug for cancer chemoprevention and therapy, and we review the strength of the cumulative evidence here.
Recent Findings In the setting of cancer, a potential repurposed drug, like statins, typically goes through a cyclical history, with
initial use for several years in another disease setting, prior to epidemiological research identifying a possible chemo-protective
effect. However, further information is required, including review of RCT data in the initial disease setting with exploration of
cancer outcomes. Additionally, more contemporary methods should be considered, such as Mendelian randomization and
pharmaco-epidemiological research with “target” trial design emulation using electronic health records. Pre-clinical and tradi-
tional observational data potentially support the role of statins in the treatment of cancer; however, randomised trial evidence is
not supportive. Evaluation of contemporary methods provides little added support for the use of statin therapy in cancer.
Summary We provide complementary evidence of alternative study designs to enable a robust critical appraisal from a number of
sources of the go/no-go decision for a prospective phase III RCT of statins in the treatment of cancer.
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Introduction
From a global cancer perspective, repurposing established
medicines for a new clinical indication is potentially an
important strategy, particularly due to the increasing can-
cer burden in low- and middle-income countries where
access to costly new therapies and technologies is limited.
A major advantage of assessing repurposing possibilities
is that many of the early steps in the drug development
pathway, i.e., phase I/II trials establishing safety and tol-
erability, are already completed and generic formulations
available. However, phase III randomised controlled trials
(RCTs) are still needed to establish efficacy for the new
clinical indication.
For new drugs, there is an established developmental
pathway from pre-clinical evidence, through first in man
studies, phase I and II trials leading to a phase III RCT
(Fig. 1a). For repurposed drugs, the evidence base is dif-
ferent and there is no established consensus as to what this
should comprise and how it should be appraised in order to
prioritise potential repurposed drugs for phase III evalua-
tion. Pre-clinical evidence can be complemented by
Fig. 1 a Standard drug development pathway97. b Proposed drug development pathway for repurposed drugs
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epidemiological data, previous randomised trials, and
Mendelian randomization or more modern genetic studies.
Some would argue that any low-cost, established drug
with minimal toxicity and some evidence of anti-tumour
activity is a candidate for phase III evaluation particularly
in tumour types with poor outcomes. Proponents of such
an approach argue there is little to lose, as long as the trial
participants are fully informed. However, a phase III trial
particularly in the adjuvant setting is a costly, resource in-
tensive, and long-term undertaking and the scientific rationale
underpinning the trial needs to be robustly evaluated.
Statins, the most widely prescribed lipid-lowering agents,
are inhibitors of the 3-hydroxy-3-methylglutaryl-coenzyme A
reductase (HMGCR) enzyme, the rate-limiting step in the
mevalonate pathway (Fig. 2). Numerous large RCTs in a
range of populations have confirmed the role of statins for
the prevention and treatment of cardiovascular and cerebro-
vascular disease, and they have become well-established ther-
apy in this setting [1–3]. Beyond their lipid-lowering action
and cardiovascular benefits, evidence has suggested statins
may have multiple pleiotropic actions, including anti-inflam-
matory, antioxidant, anti-proliferative, and immunomodulato-
ry effects, potentially yielding clinically relevant anticancer
properties [4].
The existence of extensive randomised data evaluating
statins for cardiovascular disease (CVD) provides an opportu-
nity to interrogate these data for evidence of clinical effects on
cancer outcomes. A similar approach was taken for aspirin.
Meta-analyses of individual patient data from large RCTs of
aspirin use in CVD prevention demonstrated significant re-
ductions in cancer incidence, and risk of metastases
[5]. These findings supported results from observational
and pre-clinical data [6, 7]. Consequently, aspirin is
now under investigation in several RCTs for the preven-
tion of metastases [8].
Similarly, attention has turned to statins as a repurposed
drug in the treatment of cancer. This review summarises the
possible anticancer mechanism of action of statins and
the breadth of evidence for and against its use in the
prevention and treatment of cancer. Relative to previous
reviews, a wider range of data sources and methods of
evaluating the data is presented here, including the role
of pharmaco-epidemiological research and Mendelian ran-
domization to minimise potential confounding limiting the
evaluation of observational studies [9]. We also present a nov-
el model for assessing other drugs where there is potential for
repurposing (Fig. 1b).
Potential Anticancer Mechanisms of Action
of Statins
Inhibition of HMGCR leads to a decrease in mevalonate and
downstream cholesterol biosynthesis, as well as the inhibition
of other isoprenoid metabolites, required for a number of cel-
lular functions and post-translational modification of cell sig-
nalling proteins [10] (Fig. 2). Several in vitro studies have
demonstrated that statins act to inhibit a number of the
Fig. 2 The mevalonate pathway
and possible mechanism of action
of statins
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hallmarks of cancer, including inhibition of angiogenesis, in-
duction of apoptosis, repression of tumour metastases, and
inhibition of tumour cell growth [11] (Fig. 2). Statins vary in
their solubility, with hydrophilic statins more hepato-selective
and lipophilic statins achieving a higher level of exposure in
non-hepatic tissue [12]. Based on this classification, lipophilic
statins, including simvastatin and atorvastatin, are considered
to exert more pleiotropic effects and are, therefore, potentially
more effective as anticancer therapies.
In vivo experiments have proven more conflicting. Early
studies in animal models raised concerns that statins may have
carcinogenic properties [11]. In rodent studies, administration
of fluvastatin was shown to induce thyroid neoplasms and
forestomach papillomas [13], lovastatin induced liver tumours
[14], and administration of simvastatin led to follicular cell
adenomas [15]. In studies demonstrating a procarcinogenic
effect, the doses of statins used were far higher than the bio-
logically relevant concentrations used to treat hypercholester-
olaemia in humans, possibly explaining these detrimental ef-
fects. Although some animal models have demonstrated anti-
carcinogenic effects of statins [16], a review of all available
rodent carcinogenicity data for lipid-lowering agents conclud-
ed that, on balance, both statins and fibrates promoted cancer
in rodents even at the equivalent concentrations prescribed in
humans [17].
Statins and the Prevention
of Cancer—Observational Studies
A number of observational studies have supported the hypoth-
esis of a protective effect of statins in terms of cancer risk
[18–24]. One of the largest of these evaluated approximately
300,000 patients, using the Danish Cancer Registry, and
found that any statin use reduced cancer incidence with an
adjusted rate ratio (RR) for cancer overall of 0.86 (95% con-
fidence interval (CI) 0.78 to 0.95) [25].
However, a number of other meta-analyses of observational
studies of individual cancers have both disputed and supported
a role for statins in the protection against cancer in equal mea-
sure [26–35]. One large meta-analysis including 25 observa-
tional studies and 17 randomised studies reviewed the effect of
statins on all cancers, finding no effect on overall incidence
(relative risk (RR) 0.96, 95% CI 0.72–1.2) [26]. However, a
meta-analysis of 20 case-control studies suggested a significant
beneficial association between statin use and risk of any cancer
[35]. Although both large studies, these discrepancies reflect
the inherent potential for bias, confounding, and heterogeneity
between observational studies which could provide alternative
explanations for any associations seen. An umbrella review
and re-analysis of data from 43 meta-analyses, performed to
determine the strength of the evidence available, found a sta-
tistically significant effect of statins on reducing cancer
incidence in 10 types of cancer when using traditional
methods; however, when the evidence was graded, accounting
for between-study heterogeneity and potential bias, it was not
found to be “convincing” for any cancer type [36].
Statins and the Prevention
of Cancer—Randomised Studies
A significant proportion of the evidence base underpinning
the evaluation of aspirin as an anticancer drug originated from
the long-term follow-up of large RCTs primarily designed to
assess aspirin’s cardiovascular benefits [5, 37]. However, in
similar randomised vascular trials of statin use, no difference
has been shown in the incidence and risk of cancer. In the
largest of these, the Heart Protection Study, 20,000 patients
were randomised to 40 mg of simvastatin or placebo, with a
reduction in cholesterol and proportional decrease in major
vascular events seen in the statin cohort [38]. However, after
a mean 11-year follow-up of survivors (n = 17,519), there was
little evidence of a difference in the incidence of a first diag-
nosis of any cancer, either in-trial (first 5 years) or post-trial
(subsequent 6 years) [39], or no difference by cholesterol level
or tumour subtype.
In the early 2000s, a number of other RCTs assessing the
effect of statins on the primary and secondary prevention of
CVD consistently demonstrated vascular benefits. However, a
large meta-analysis of 26 RCTs including 86,936 participants
with 6662 incident cancers and 2407 cancer deaths showed
that statins had a neutral effect on both incidence of cancer and
cancer deaths, regardless of cancer subtype [40, 41]. To ad-
dress specific concerns regarding the effect of lowering low-
density lipoprotein (LDL) cholesterol with statins and poten-
tial risk of cancer, the Cholesterol Treatment Trialists’ (CTT)
Collaboration performed a series of meta-analyses of individ-
ual patient data (n = 174,149) from 27 randomised vascular
trials. They demonstrated that reducing LDL concentration
with statins had no effect on either cancer incidence (RR per
1.0 mmol/L LDL reduction 1.00, 95% CI 0.96–1.04) or mor-
tality (RR 0.99, 95% CI 0.93–1.06) [3, 42–44]. Statins were
used for a median of 5 years, and no difference emerged re-
gardless of whether trials were of statins versus control or
trials of a more versus less intensive statin regime. Analyses
of the effect of statins on individual cancers (23 different pri-
mary sites), by gender, older age, or statin type, were also
consistent for a lack of association [45•]. These meta-
analyses are probably the strongest available evidence to sug-
gest that statins are unlikely to reduce the risk of incident
cancer overall, at least in the short to medium term.
The implications for cancer-related mortality may be less
clear. The included trials were for the primary and secondary
prevention of CVD and the majority of patients enrolled
would not be expected to have a cancer diagnosis at the time
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of randomization. Indeed, only cancers diagnosed after ran-
domization were considered (1.4% developed cancer per year
after randomization in the CTT study [46]), and it is not clear
how many and for how long patients received the study drug
after diagnosis. Whilst detailed information on statin use after
a cancer diagnosis is not available in this data, statins are not
routinely discontinued during cancer therapy, and therefore,
some effect on mortality might be expected if there was a
therapeutic role. Detailed follow-up of the data would be use-
ful to make a more informed inference about the effect of
allocation to statins on mortality outcomes in patients with
cancer from these meta-analyses.
The Role of Pharmaco-epidemiological
Research
In contrast to the usual pathway for new drug development
(phase I, II, and III trials), the rationale for a trial of a
repurposed drug in the setting of cancer prevention or treat-
ment can be informed by pharmaco-epidemiological research.
In the past decade, there has been a marked proliferation in
such research, due to a growing availability of population-
based datasets drawn from a number of routinely collected
health data sources (including electronic health records, phar-
macy records, disease registries and outcome datasets) [47,
48]. Such research can leverage the availability of accurate
prescription data in defined cohorts, with comprehensive data
on relevant covariates and outcomes, to estimate the real-
world effectiveness of statins in cancer prevention and treat-
ment. There are notable examples where pharmaco-
epidemiology has critically informed the justification for sim-
ilar trials of other repurposed drugs in cancer prevention and
treatment [8, 49]. Indeed, the AspECT trial, a 2 × 2 phase III
trial of esomeprazole and aspirin for the prevention of a com-
posite outcome of death, adenocarcinoma, and high-grade
dysplasia in patients with Barrett’s oesophagus, was justified
in part on the available pharmaco-epidemiological evidence
and, ultimately, yielded some evidence for a chemo-protective
effect consistent with this research [49]. However, there are
also well-known examples where observational studies con-
flict with randomised data [50]. A common explanation for
such discrepancies is the propensity for observational research
to be susceptible to residual confounding, due to an imbalance
of prognostic factors between treatment groups not accounted
for in analyses, brought about by a lack of random treatment
assignment [51]. However, observational studies can differ
from randomised trials in other important ways to explain
such discrepancies, including their design and analysis, with
residual confounding a lesser concern in some instances [52].
To minimise these flaws, observational study design requires
the emulation of a pragmatic hypothetical target trial (a
randomised trial that would answer the question of interest),
including explicit description of the causal framework, speci-
fying the protocol of the target trial, robust reporting of study
design, and a structured process for the analysis of study lim-
itation [47, 53]. Use of such an approach in large healthcare
datasets provides the opportunity to assess the association
between a treatment and outcome using real-world data and
helps to reduce the discrepancies between the effect estimates
from observational studies and randomised trials [54••]. These
are welcome steps towards improving the application of re-
sults from observational research, including, in this context, to
improve their utility in informing the justification for or
against a trial of adjuvant statin therapy.
An analysis of the electronic health records of 733,804 UK
adults, explicitly emulating a target trial of statins and cancer,
found little evidence to indicate that statin therapy influences
cancer incidence after 10-year follow-up [54••], regardless of
cancer subtype, and consistent with findings of the CTT
Collaboration. The authors further demonstrated that the fail-
ure in replicating observational study results arose from the
deviation from the basic principles of a trial design [54••].
Eligibility criteria included LDL cholesterol level <
5 mmol L−1,which may have introduced some confounding,
channelling people with diabetes into the statin group (diabe-
tes being an indication for statin therapy irrespective of LDL),
and diabetes is a known risk factor for cancer. However,
pharmaco-epidemiological research could be utilised much
like this example to supplement the evidence base for a phase
III repurposed drug trial, but perhaps also to provide more
timely results to support clinical decision making.
The Role of Mendelian randomization
Conventional observational epidemiological studies are vul-
nerable to various biases (e.g., residual confounding, reverse
causation, and measurement error) which undermine causal
inference. Mendelian randomization (MR) uses genetic vari-
ants to proxy risk factors to generate more reliable evidence in
support of causal effects of these factors on health outcomes in
observational settings [9]. Since germline genetic variants are
randomly assorted at meiosis and fixed at conception, MR
analyses should be less prone to confounding than conven-
tional observational studies (e.g., by indication, lifestyle fac-
tors) and are not subject to reverse causation bias. Further,
measurement error in genetic studies is often low and MR
estimates the life-long effects of risk factors on health out-
comes, allowing sufficient time for diseases with long latency
periods—like cancer—to develop an advantage over second-
ary analyses of short-term RCTs. MR relies on sound knowl-
edge of the mechanism of action and existence of a relevant
genetic variant, and therefore, it may not be possible or useful
for all drug evaluations. However, findings from well-
conducted and adequately powered MR studies, with
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appropriate sensitivity analyses to evaluate the assumptions of
MR [55], could provide a useful contribution to the evidence
synthesis of statins as a potential preventive agent or therapeu-
tic treatment for cancer.
A commonly employed approach for inferring causal ef-
fects of statins on cancer in an MR context is to utilise genetic
variants in the gene encoding the drug target of statins,
HMGCR, that are robustly associated with LDL cholesterol
levels as proxies for pharmacological inhibition of this drug
target. One such study employed the LDL cholesterol-
lowering T-allele of rs12916 (located within HMGCR) as a
proxy for HMG-CoA reductase inhibition to examine the ef-
fects of its inhibition on risk of cancer in the Malmö Diet and
Cancer Study [56]. The authors reported little evidence for an
effect of HMGCR inhibition on overall cancer risk (HR equiv-
alent to 0.07 mmol/L lowering of LDL cholesterol 0.99, 95%
CI 0.95–1.02), though statistical power was modest for this
analysis (n = 6528 cases). In an analysis of 22,773 men with
prostate cancer and 23,050 controls in the Prostate Cancer
Association Group to Investigate Cancer Associated
Alterations in the Genome (PRACTICAL) consortium, a
weak protective effect was reported of the rs12916-T variant
with prostate cancer risk (OR 0.97, 95% CI 0.94–1.00; p =
0.03) [57], and little evidence apparent of an association with
stage or tumour grade. Three variants in HMGCR were eval-
uated in relation to risk of breast cancer in 122,977 cases and
105,974 controls in the Breast Cancer Association
Consortium (BCAC) [58]. Similarly weak evidence was dem-
onstrated for a protective effect of HMGCR inhibition on
cancer risk (OR equivalent to 1 mmol/L lowering of LDL
cholesterol 0.86, 95% CI 0.73–1.02, p = 0.09) [58], with com-
parable odds when analyses were restricted to status of
oestrogen receptor. Most recently, a study of genetically
proxied HMGCR inhibition, equivalent to a 1-mmol/L reduc-
tion in LDL cholesterol, demonstrated robust evidence of a
lower risk of epithelial ovarian cancer (OR 0.60, 95% CI
0.43–0.83; p = 0.002) in both the general population and in
BRCA 1/2 mutation carriers (HR 0.69, 95% CI 0.51–0.93;
p = 0.01) [59••], consistent with pre-clinical and epidemiolog-
ical studies, perhaps warranting further investigation in this
high-risk group. Going forward, the integration of MR with
other complementary genetic approaches may provide a
promising opportunity for validating the effects of drug
targets like HMGCR on cancer outcomes. For example,
Zheng et al. have reported that combining evidence
from MR and colocalization analysis, a technique that
helps to distinguish shared causal variants across traits
from genetic confounding due to linkage disequilibrium,
can substantially increase the likelihood of predicting
positive clinical trial outcomes leading to regulatory ap-
proval of new drugs [60].
Extension of the MR approach to various other cancers
within the context of adequately powered datasets along with
the application of this approach to the study of cancer progres-
sion or recurrence [61], rather than cancer incidence, remains
a fruitful area of investigation. The latter is important as the
utility of a particular agent in the context of risk reduc-
tion (primary prevention) may not necessarily translate
to a therapeutic effect in the context of disease progres-
sion (tertiary prevention), and vice versa. Insights
gained from the use of MR in interrogating causal rela-
tionships between statin use, cancer occurrence, and
cancer outcomes can therefore provide complementary
evidence to other study designs on the potential role
of long-term statin therapy in reducing incidence or pro-
gression of cancer.
Table 1 summarises the types of evidence evaluating statin
therapy in the prevention of cancer.
Statins and the Adjuvant Treatment of Cancer
Evaluating “Traditional” Evidence for Statins in the
Treatment of Cancer
A possible role for statins in the adjuvant setting of cancer has
been suggested by a recent in vitro study, where statins were
shown to reduce the outgrowth of metastases in two breast
cancer cell lines [62]. It has therefore been suggested that
statins could delay breast cancer recurrence and reduce mor-
tality [63]. A number of population-based cohort studies have
demonstrated that statins may reduce cancer-specific mortality
in breast, colorectal, and lung cancer [64–66]. One of the
largest of these reviewed statin use in Danish residents diag-
nosed with stage I–III invasive breast cancer (n = 18,769).
Simvastatin users developed approximately 10 fewer breast
cancer recurrences per 100 women after 10 years, with 10-
year adjusted HR 0.70 (95%CI 0.57–0.86) [67, 68]. In a meta-
analysis of 10 observational studies, including 32,373 patients
with breast cancer, lipophilic statin use was shown to be
associated with improved recurrence-free survival (HR
0.64, 95% CI 0.53–0.79) at 5-year follow-up [69].
However, many of these studies are affected by collider
stratification bias—unmeasured confounding induced by
selected bias—and an evaluation of alternative explana-
tions is crucial [70].
The potential survival benefit of statins for patients with
malignancy has been further evaluated in a meta-analysis of
95 cohort studies, including 1,111,407 individuals. Subgroup
analyses according to initiation of statins showed that post-
diagnosis statin use was associated with a significant improve-
ment in recurrence-free survival (HR 0.65; 95% CI 0.54–
0.79), which was less convincing for pre-diagnosis use (HR
0.86, 95% CI 0.77–0.96); a similar association was seen for
overall survival (OS) [71]. Most studies identified were in
prostate, breast, and colon cancer, with consistent benefits
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seen across these three tumour types. However, a recent um-
brella review of meta-analyses, an appraisal of high-level ev-
idence, evaluating data from 112 meta-analyses of observa-
tional studies and 144 meta-analyses of RCTs, found only
class III (suggestive) evidence of decreased cancer-related
mortality in patients with cancer who had statins post-diagno-
sis, concluding limited convincing evidence of an effect of
statins on cancer mortality in the adjuvant setting [72].
The evidence for the use of statins post diagnosis of cancer
appears most abundant in the setting of breast cancer [69, 73,
74]. However, as with other tumour types, most data exists in
the observational setting, with little randomised evidence. The
Breast International Group’s large RCT (BIG 1-98) appears to
be the only observational study of statin use in the adjuvant
setting of breast cancer in the context of a randomised con-
trolled trial of endocrine therapy. Survival of 8010 postmen-
opausal women with early-stage, hormone receptor–positive
breast cancer was assessed, in whom 789 initiated cholesterol-
lowering medication (CLM) during endocrine therapy
[75]. In patients commenced on CLM (including non-
statins), an association with improved disease-free sur-
vival (HR 0.79; 95% CI 0.66 to 0.95), breast cancer–
free interval (HR 0.76; 95% CI 0.60 to 0.97), and dis-
tant recurrence–free interval (HR 0.74; 95% CI 0.56 to
0.97) was demonstrated [75].
Pharmaco-epidemiological Research in the Adjuvant
Setting of Cancer
The majority of observational research examining the associ-
ation between statin use and survival after a diagnosis of can-
cer compares outcomes between current users (including
prevalent users) and never users. This answers a fundamental-
ly different question to that posed by RCTs: whether alloca-
tion to statins (new users) compared with no statins at the
point of randomization affects survival. There have been con-
siderable methodological advancements to improve consisten-
cy of estimates from observational research with trials, includ-
ing new-user designs (which restricts analysis to individuals
under observation at the start of the treatment of interest) [76]
and their incorporation into a wider paradigm shift: emulation
of a target trial using observational datasets [53]. The latter
requires the explicit alignment of the protocol for an observa-
tional study to that of the hypothetical “target” trial (described
previously), specifically with regard to the eligibility criteria,
treatment strategies, assignment procedures, outcome, causal
contrasts of interest (intention to treat and per-protocol ef-
fects), and analysis plan [53]. To date, a single study has
employed such an observational analogue of a target trial in
this context—a retrospective analysis of US SEER
(Surveillance, Epidemiology, and End Results) data from
17,372 patients. This study found that initiation of statins
within 6 months after cancer diagnosis (stages I–III colorectal,
breast, prostate, and bladder) did not improve 3-year cancer-
specific or overall survival [77]. This approach accounted for
potential selection and immortal time bias, and the effect of
residual confounding was likely to be negligible (HR for OS
1.00, 95% CI 0.88–1.15), although longer-term follow-up is
important. The application of this methodology to other can-
cer types would be welcome in informing the decision to
proceed to a trial.
Evidence from Mendelian randomization
There is now a large body of evidence using MR to evaluate
the effect of genetic risk on cancer incidence, with a number
specifically evaluating HMGCR inhibition. However, few
studies have attempted to identify variants associated with
cancer progression, and those that have are mostly small
[61, 78]. A number of issues have been identified in
Mendelian randomization of progression61. Compared to
cancer incidence, which is usually a binary outcome, disease
progression is more complex to measure and harder to define.
There is an increased potential for confounding through col-
lider bias, leading to a possible spurious association between
the genetic variant and progression. Furthermore,MR requires
availability of large data sets with detailed follow-up of both
progression and genetic data [61]. Therefore, for a MR study
of progression to be successful, large, and likely collaborative,
RCTs collecting DNA as a standard are required. To date, few
studies have used MR to identify factors influencing disease
progression [78–80], and to our knowledge, none evaluating
HMGCR inhibition as a proxy for statin therapy.
Randomised Trials Investigating Statins
in Cancer
Most randomised trials investigating statins in cancer have
been in advanced cancers, with few in the adjuvant setting,
and most-earlier phase (non-confirmatory) studies with rela-
tively small sample sizes (Table 2).
Any favourable effects of statins on cancer-related mortal-
ity apparent from epidemiological data have not always been
corroborated by clinical trials, and the trial evidence demon-
strated in Table 2 has not all been sufficiently robust to con-
firm or refute the effectiveness of statins in cancer. In Kawata
et al.’s phase II study of advanced hepatocellular cancer, pa-
tients received treatment with transcatheter arterial embolisa-
tion and 5-fluorouracil chemotherapy and were randomised to
40 mg of pravastatin or control, with a doubling of median OS
seen from 9 to 18 months (p = 0.006) [81]. This study had a
sample size of only 83 patients; and the findings were subse-
quently not replicated in the PRODIGE-11 trial, an RCT of
323 patients with advanced hepatocellular carcinoma
randomised to first line sorafenib-pravastatin (40 mg)
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combination therapy or sorafenib alone, which demonstrated
no significant difference in OS between treatment arms [89].
The justification to proceed with a phase III multicentre trial in
this context was based on more traditional evidence from pre-
clinical and observational studies, one meta-analyses and an
initial phase II study, with no contribution to the evidence base
from more contemporary methods.
A number of other trials are currently underway; however,
the use of more contemporary methods to support the go/no-
go decision in proceeding with a clinical trial may help to
reduce the likelihood of negative trials.
The Tolerability of Statin Therapy
Themodel for evaluating repurposed drugs should consider its
toxicity and tolerability, particularly in the adjuvant setting,
where significant or chronic toxicity may limit adherence. A
well-documented adverse effect of statin therapy is muscle
toxicity, including myopathy and rhabdomyolysis.
Myopathy occurs in fewer than 1 in 10,000 individuals, al-
though risk is considered related to both statin type and dose
[90]. Persistent and asymptomatic increases in serum transam-
inases have been reported, although usually recover on dis-
continuation. There have however been rare post-marketing
reports of hepatic failure. Generally, statins are considered
well tolerated, and reasonably good 5-year compliance has
been demonstrated in prior RCTs [38]. However, meta-
analyses of individual patient data evaluating the safety of
patients enrolled onto RCTs of statins in cardiovascular dis-
ease would provide a more comprehensive summary of the
risk of adverse events. The CTT Collaboration is currently
examining this data [91] and evaluation of safety would be
an important part of any new phase III cancer trial.
A Potential Model for Evaluating Repurposed
Drugs in Cancer Chemoprevention
Figure 1a demonstrates the conventional pathway of drug de-
velopment. Following the discovery of a promising com-
pound, supporting evidence from pre-clinical and observa-
tional data typically leads to clinical trials evaluating safety
and efficacy. On average, the time between drug discovery
and clinical trial is 9 years, with a huge cost involved, and
success rate of less than 10% [92, 93]. Compared to the tradi-
tional drug discovery process, drug repurposing can consider-
ably reduce the cost and time to bring a new treatment to
patients, with many of the early steps in the drug development
pathway already completed. The main justification for reusing
licenced drugs for a new indication is that they have known
mechanisms of actions and toxicity profiles [94]. However,
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of efficacy remains the same [95], with overall success rate
shown to be less than 6%, much like new oncological drug
discovery [92, 96]. Therefore, careful consideration is re-
quired before embarking on a clinical trial [94]. The well-
established model for drug discovery (Fig. 1a) is not designed
for drug repurposing [97]. Major efforts need to be made to
improve the rate of efficacy, perhaps considering a new
adapted model for evaluating repurposed drugs. Figure 1b
proposes a new evidence framework, particular to repurposed
drugs, suggesting concurrent appraisal of already available
data and the review of further evidence, prior to conducting
a large RCT.
Conclusion
In conclusion, whilst most pre-clinical and observational evi-
dence appears to support the use of statins in the prevention of
cancer, results from the randomised vascular setting,
pharmaco-epidemiological research using a target trial design,
and evidence from MR have all been less convincing in most
tumour types. There is little supportive evidence of the bene-
ficial effects of statins as a treatment for cancer from phase III
trials; however, most inferences have been limited to the non-
curative setting. The challenge is, therefore, to weigh up the
evidence from all sources as systematically and fairly as pos-
sible, as proposed by our model for evaluating repurposed
drugs (Fig. 1a, b), to decide whether a trial in the adjuvant
setting is justified on a tumour site-by-site basis. Further eval-
uation of the role of statins in the adjuvant setting may be
justified, with breast cancer being one such candidate disease
site to potentially investigate based on the evidence presented
here. Future observational research emulating a hypothetical
RCT, “a target trial”, in the adjuvant setting, and use of
Mendelian randomization may help inform the decision to
proceed to a potential phase III RCT of a repurposed drug.
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